What’s the current market cap for NewAmsterdam Pharma Company N.V. stock?

NewAmsterdam Pharma Company N.V. (NAMS) has a market cap of $3.5bn as of June 17, 2026.

What is the P/E ratio for NewAmsterdam Pharma Company N.V. stock?

The price to earnings (P/E) ratio for NewAmsterdam Pharma Company N.V. (NAMS) stock is 0 as of June 17, 2026.

Does NewAmsterdam Pharma Company N.V. stock pay dividends?

No, NewAmsterdam Pharma Company N.V. (NAMS) stock does not pay dividends to its shareholders as of June 17, 2026.

When is the next NewAmsterdam Pharma Company N.V. dividend payment date?

NewAmsterdam Pharma Company N.V. (NAMS) stock does not pay dividends to its shareholders.

What is the beta indicator for NewAmsterdam Pharma Company N.V.?

NewAmsterdam Pharma Company N.V. (NAMS) has a beta rating of 0.03. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy NewAmsterdam Pharma Company N.V. stock | $NAMS Share Price

13:30

15:10

16:45

18:25

20:00

About NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Ticker

$NAMS

Sector

Health

Primary listing

NASDAQ

Employees

100

Headquarters

Naarden, Netherlands

Website

www.newamsterdampharma.com

NAMS Metrics

BasicAdvanced

$3.5bn

-$1.78

0.03

Bulls say / Bears say

Strong cash position of $707.3 million as of March 31, 2026 provides runway through key Phase 3 readouts and potential product launches without immediate need for external financing. (GLOBE NEWSWIRE)

Initial blinded review of PREVAIL trial data showed Year 1-to-Year 2 MACE event rate lower than expected, prompting an interim analysis in 4Q 2026 and suggesting promising efficacy signals for obicetrapib. (GLOBE NEWSWIRE)

NewAmsterdam has completed enrollment in the REMBRANDT Phase 3 trial and expects topline data from the RUBENS trial by year-end 2026, demonstrating robust clinical progression across its pipeline. (GLOBE NEWSWIRE)

Net loss widened to $48.4 million in Q1 2026 from $39.5 million in Q1 2025, underscoring persistent unprofitability ahead of any commercial revenues. (GLOBE NEWSWIRE)

Q1 2026 revenue remained flat at $3.0 million compared to the prior year period, indicating minimal top-line growth and continued dependency on Menarini supply agreements. (GLOBE NEWSWIRE)

Full PREVAIL cardiovascular outcomes trial may not conclude until end-2027 if the interim analysis does not halt the study, potentially delaying regulatory submissions and market entry. (GLOBE NEWSWIRE)

Data summarised monthly by Lightyear AI. Last updated on 16 Jun 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NAMS

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Strong cash position of $707.3 million as of March 31, 2026 provides runway through key Phase 3 readouts and potential product launches without immediate need for external financing. (GLOBE NEWSWIRE)

Net loss widened to $48.4 million in Q1 2026 from $39.5 million in Q1 2025, underscoring persistent unprofitability ahead of any commercial revenues. (GLOBE NEWSWIRE)

Q1 2026 revenue remained flat at $3.0 million compared to the prior year period, indicating minimal top-line growth and continued dependency on Menarini supply agreements. (GLOBE NEWSWIRE)

Data summarised monthly by Lightyear AI. Last updated on 16 Jun 2026.